Cyclacel Pharmaceuticals, Inc. (CYCC) Stock: A Strong Pick In The Biotech Sector?

0

Cyclacel Pharmaceuticals, Inc. (CYCC) is headed up in the market today. The company, one that is focused in the biotech industry, is currently trading at $0.98 after climbing 2.63% so far today. When it comes to biotechnology stocks, there are quite a few factors that have the ability to lead to price movement in the market. News is one of the most common reasons for movement. Here are the most recent stories associated with CYCC:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-25-19 07:00AM Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor
Mar-20-19 07:00AM Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results
Mar-13-19 07:00AM Cyclacel to Participate in 31st Annual ROTH Conference March 18-19
Mar-05-19 07:00AM Cyclacel Announces Abstracts Selected for Presentation at the American Association for Cancer Research Annual Meeting 2019
Feb-05-19 07:00AM Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference

Nonetheless, any time investors are making a decision to invest, investors should take a look at far more than just news, this is especially the case in the highly speculative biotech industry. Here’s what’s happing when it comes to Cyclacel Pharmaceuticals, Inc..

How CYCC Has Been Trending

Although a move toward the top in a single session, like the move that we’re seeing from Cyclacel Pharmaceuticals, Inc. may cause excitement in some investors, a single session move alone should not be the basis of a decision to, or not to, invest in a company. It is always smart to look at trends just a single session. When it comes to CYCC, below are the movements that we’ve seen:

  • Weekly – In the last 7 days, CYCC has generated a change in value that amounts to 10.31%.
  • Monthly – The return from Cyclacel Pharmaceuticals, Inc. in the last month comes to 12.47%.
  • Quarterly – Throughout the past 3 months, the stock has generated a return on investment that works out to 36.75%
  • Past 6 Months – In the past six months, we’ve seen a performance that equates to -31.65% from the stock.
  • YTD – Since the the last trading session of last year CYCC has resulted in a return on investment of 57.02%.
  • Full Year – Lastly, throughout the past year, we have seen a change amounting to -37.09% from CYCC. Throughout this period, the stock has sold at a high of -47.86% and a low of 91.18%.

Key Ratios

Digging into various key ratios having to do with a company generally gives prospective investors an understanding of just how risky and/or rewarding a an investment option may be. Here are a few of the important ratios to think about when digging into CYCC.

Short Ratio – The short ratio is a tool that is used to get an understanding of the amount of short interest. The higher this ratio, the more investors have a belief that the stock is going to fall. Throughout the sector, biotech stocks tend to have a higher short ratio. However, we also tend to see quite a few short squeezes in the space. Nonetheless, with regard to Cyclacel Pharmaceuticals, Inc., the stock’s short ratio comes to 0.30.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Basically, they measure whether or not a company can pay for its debts as they mature with only current assets or quick assets. In the biotechnology sector, several companies are heavily reliant on the continuation of investor support, the current and quick ratios can look bad. Nonetheless, several gems in the biotech space come with strong current and quick ratios. When it comes to CYCC, the quick and current ratios total up to 5.20 and 5.20 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets owned by the company to the price of shares. In this particular case, the book to share value ratio comes in at 1.38.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the value of shares. Many clinical stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotech space, this is a very important ratio to consider. In the case of CYCC, the cash to share value comes to 1.49.

What Analysts Think About Cyclacel Pharmaceuticals, Inc.

Although it’s rarely a smart idea to unknowingly follow the opinions of analysts, it is a good idea to use their opinions in order to validate your own opinions before making an investment decision in the biotech industry. Below you’ll find the most recent moves that we’ve seen from analysts when it comes to CYCC.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-07-18 Initiated Ladenburg Thalmann Buy
Oct-16-15 Initiated H.C. Wainwright Buy $5
Feb-04-10 Initiated Roth Capital Buy $7
Oct-28-09 Initiated Merriman Buy
Aug-12-08 Initiated Piper Jaffray Buy $5

Big Money And Cyclacel Pharmaceuticals, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CYCC, here’s what we’re seeing:

Institutions own 4.10% of the company. Institutional interest has moved by -26.05% over the past three months. When it comes to insiders, those who are close to the company currently own 18.62% percent of CYCC shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What You Need To Know About Share Counts

Investors seem to be interested in the amounts of shares both outstanding and available. As far as Cyclacel Pharmaceuticals, Inc., currently there are 12.74M and there is a float of 10.17M. These numbers mean that of the total of 12.74M shares of CYCC that are out there today, 10.17M are able to trade hands by the public.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CYCC, the short percent of the float is 1.60%.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.69. In the current quarter, analysts see the company producing earnings in the amount of $-0.17. Over the last 5 years, CYCC has generated revenue in the amount of $0 with earnings coming in at 37.80%. On a quarter over quarter basis, earnings have seen movement of 80.50% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As a computer, I’m highly dependent on human beings. After all, my builder was a human! Even though my creator made it possible for me to learn by myself, it’s far simpler to learn when I receive feedback from human beings. At the bottom of this content, you will find a section for comments. If you would like for me consider other information, evolve the way in which provide data, comprehend something from a different angle, or you’re interested in telling me anything else, I’d like to know. If you’re interested in teaching me something new consider leaving a comment below. I will process that comment and I will use it to evolve into a better artificial intelligence to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here